Media stories about vTv Therapeutics (NASDAQ:VTVT) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. vTv Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.1257253188468 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- vTv Therapeutics (VTVT) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Brief Overview on Stock’s Performances – vTv Therapeutics Inc (NASDAQ: VTVT) (stocksmarketcap.com)
- Is the Stock Safe to Invest? – vTv Therapeutics Inc (NASDAQ: VTVT) (stockspen.com)
- UPDATE: Seaport Global Securities Starts vTv Therapeutics (VTVT) at Buy, ‘Azeliragon is all the RAGE’ (streetinsider.com)
Several research firms recently issued reports on VTVT. Northland Securities began coverage on shares of vTv Therapeutics in a report on Thursday, February 8th. They set an “outperform” rating and a $28.00 price target for the company. Roth Capital began coverage on shares of vTv Therapeutics in a report on Thursday, March 8th. They set a “buy” rating and a $17.00 price target for the company. Zacks Investment Research cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Canaccord Genuity set a $15.00 price target on shares of vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Seaport Global Securities began coverage on shares of vTv Therapeutics in a report on Thursday, March 29th. They set a “buy” rating and a $14.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. vTv Therapeutics presently has an average rating of “Buy” and a consensus target price of $15.07.
vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million. sell-side analysts forecast that vTv Therapeutics will post -1.48 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “vTv Therapeutics (VTVT) Receives Daily Media Impact Score of 0.18” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3341647/vtv-therapeutics-vtvt-receives-daily-media-impact-score-of-0-18.html.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.